

REMARKS
---------

**Status of the Claims**

No amendments to the claims have been made. Claims 1-11 are still pending.

**Summary of Telephone Conversation with SPE Sreeni Padmanabhan**

The undersigned telephoned Mr. Padmanabhan about what action could be taken with regard to the inadvertently filed Notice of Appeal of 12 December 2003. Mr. Padmanabhan indicated that the 112, first paragraph rejection could be withdrawn and that the claims would be allowable if the ODP rejection was addressed. As the Notice of Appeal had to be taken as valid, he could not simply remove the Appeal from the record without first abandoning the case. The applicants have petitioned to revive the application and have reproduced the response from 8 October 2003 (entered by the PTO on 9 October) with the addition of a terminal disclaimer.

Presuming that all of the issues concerning abandonment have been addressed, it is believed that the claims are not in condition for allowance.

**Obviousness-type double patenting (ODP) rejection**

Claims 1-11 were rejected over U.S. Patent 6,592,883 (SN: 09/640,528) under obviousness-type double patenting grounds. A terminal disclaimer is being filed by the applicants to overcome this rejection.

**35 U.S.C. 112, first paragraph rejection**

Claim 8 was rejected as being enabling for "substances effective against acne" but not astringents or anti-microbially effective substances. As both of these ingredients are contemplated in the specification (which includes the claims as originally filed) - see also page 17, lines 11-12, it is not clear why the examiner believes that one of ordinary skill in the art would not be able to add either of these ingredients to the preparation of claim 1.

The initial burden is on the examiner to show that the invention is not enabled as claimed. The examiner is reminded that the test for enablement is cited within MPEP 2164.01 which states:

*"The standard for determining whether the specification meets the enablement requirement was cast in the Supreme Court decision of *Mineral Separation v. Hyde*, 242 U.S. 261, 270 (1916) which postured the question: *is the experimentation needed to practice the invention undue or unreasonable? That standard is still the one to be applied.* In *re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).*

The factors for determining undue experimentation are described in MPEP 2164.01(a):

*"There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is 'undue'. These factors include, but are not limited to:*

- (A) The breadth of the claims;
- (B) The nature of the invention;

- (C) The state of the prior art;
- (D) The level of one of ordinary skill in the art;
- (E) The level of predictability in the art;
- (F) The amount of direction provided by the inventor;
- (G) The existence of working examples; and
- (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.

*In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed Cir. 1988)."

There has been no *Wands*-type analysis made; only a conclusionary statement. Therefore, the initial burden for showing lack of enablement has not yet been established.

**Closing**

Applicants also believe that this application is in condition for allowance. However, should any issue(s) of a minor nature remain, the Examiner is respectfully requested to telephone the undersigned at telephone number (212) 808-0700 so that the issue(s) might be promptly resolved.

Respectfully submitted,

Norris, McLaughlin & Marcus, P.A.

By: Howard C. Lee  
Howard C. Lee  
Reg. No. 48,104

875 Third Ave., 18<sup>th</sup> Floor  
New York, New York 10022  
(212) 808-0700

**CERTIFICATE OF MAILING**

I hereby certify that the foregoing Preliminary Amendment is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Hon. Commissioner of Patents, Washington, D.C. 20231, on the date indicated below:

Date: 17 December 2004

By: Agata Glinska  
Agata Glinska